Much of the general public believes oncology is a “sad” field. Amol Narang, and many other practicing oncologists, disagree. Learn about his inspiring profession and why he would choose to be an oncologist time and time again.
Epigenetic drugs are an emerging class of cancer therapeutics. In this article, Ph.D. candidate Roshan Chikarmane introduces Foghorn Therapeutics, its co-founder, Cigall Kadoch, and the science behind their drug development program.
Next generation cancer diagnostics are poised to change the way that cancer is detected and treated. Ph.D. candidate Roshan Chikarmane shares his perspectives on the teams and technologies that are leading the charge.
Pulitzer Prize-winning author and oncologist Siddhartha Mukherjee along with former executive vice president of the American Cancer Society and Hopkins oncologist Otis Brawley spoke with the Washington Post about how COVID-19 affects cancer outcomes.
The benefits of detecting and treating cancer at early developmental stages have long been observed by clinical oncologists. Colonoscopies as well as other methods for early detection have been estimated to prevent as many as 60% of deaths attributable to colorectal cancer by identifying and removing precancerous growths1. More broadly, patients with early stage cancer […]
It has long been known — thanks largely to work by Johns Hopkins’ own Bert Vogelstein — that cancer is a disease generally caused by an accumulation of genetic mutations. This is sometimes referred to as the somatic mutation theory.1 This hypothesis states that each time a cell divides and grows, there are opportunities for […]
In a 1909 manuscript titled “Ueber den jetzigen Stand der Chemotherapie” (“About the Current State of Chemotherapy”), Nobel laureate Paul Ehrlich proclaimed, “We must learn to aim in a chemical sense.” What did he mean? Ehrlich was referring to his “magic bullet” theory of chemical specificity, the observation that certain drugs can eliminate disease-causing entities […]
Melanoma cells stained with PTRF (in red), RPA194 (in green) and nucleus stained in blue. RPA194 is the main subunit of the RNA polymerase I (POL 1) enzyme. Our lab discovered a first-in-class small molecule that inhibits POL 1 enzyme and causes the destruction of RPA194 protein. Here, we are investigating how these proteins are […]